IGF1 and Familial prostate cancer: Having previously reported that IGF targeting affects DNA damage responses in prostate cancer cells [6, 10], we also tested xentuzumab and MK-8776 in 22Rv1 prostate cancer spheroids, again finding a combination effect of this co-treatment on spheroid growth and viability (Supplementary Fig. S6H).